FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283156175> ?p ?o ?g. }

• W4283156175 abstract "<h3>Introduction</h3> Risankizumab is a monoclonal antibody which inhibits interleukin-23, a key cytokine in the pathogenesis of IBD. It has applications in several immune mediated inflammatory diseases and has recently demonstrated superiority versus placebo as induction and maintenance treatment for moderate-to-severe Crohn’s disease (CD). A pre-approval access program (PAAP) granted use for a cohort of patients who had active disease, a previous inadequate response to all licenced biologic therapies for CD and who were ineligible for a clinical trial. We aimed to define the effectiveness and tolerability of risankizumab in this real-world, treatment refractory cohort. <h3>Methods</h3> We performed a retrospective cohort analysis of prospectively maintained data for patients starting risankizumab between January and September 2021. All patients received doses at four weekly intervals. Clinical disease activity, biochemical activity and quality of life were measured using HBI, CRP and IBD-C scores, respectively. Study evaluations were made at baseline, weeks 4 and 12. Data were analysed in GraphPad prism and are described as median (range). <h3>Results</h3> Since January 2021, 16 patients have started Risankizumab via the PAAP. We included 12 patients with CD who had completed the 12 week induction period at the time of submission. Demographics are shown in table 1. The characteristics are consistent with a more aggressive phenotype with the majority of patients (9 (75%)) having perianal involvement as well as having either stricturing (5(42%)) or internal penetrating disease (3(25%)). Nine (75%) patients had undergone prior luminal surgery, 7 of whom still had stomas, therefore were not included in the analysis for HBI. Median HBI at baseline was 2 (0-10) vs 1 (0-8) at week 4 and 1 (0-2) at week 12 and due to small patient numbers was not statistically significant. There was an improvement in IBD-C scores, although not statistically significant. Median IBD-C score at baseline was 5 (0-14) vs 10 (4-16) at week 4 and 12 (2-16) at week 12. CRP decreased from 12 mg/L (1-48) at baseline to 9 mg/L (1-20) at week 4 (p=0.13) and to 7 mg/L (1-34) at week 12 (p=0.029). Results are represented in Figure 1. Two patients experienced mild headaches, no other side effects were reported. At baseline two patients were being treated with concomitant steroids; one discontinued following induction and one has remained on steroids. No other patients initiated steroids. No patients discontinued risankizumab during the study period. <h3>Conclusions</h3> We present a heterogeneous cohort of patients with refractory CD despite multiple biologic mechanisms. Overall, there was a positive impact of risankizumab induction over a 12 week period with respect to symptoms, quality of life and CRP, showing the effectiveness of risankizumab in this refractory cohort. We will follow up, and at week 24 will objectively assess disease activity with cross sectional imaging and/or endoscopy." @default.
• W4283156175 created "2022-06-21" @default.
• W4283156175 creator A5003941121 @default.
• W4283156175 creator A5013179086 @default.
• W4283156175 creator A5022868259 @default.
• W4283156175 creator A5036405798 @default.
• W4283156175 creator A5039933427 @default.
• W4283156175 creator A5054688598 @default.
• W4283156175 creator A5062869252 @default.
• W4283156175 creator A5065018139 @default.
• W4283156175 creator A5089728798 @default.
• W4283156175 date "2022-06-01" @default.
• W4283156175 modified "2023-09-26" @default.
• W4283156175 title "P19 Risankizumab in crohn’s disease: real world experience from a pre-approval access program" @default.
• W4283156175 doi "https://doi.org/10.1136/gutjnl-2022-bsg.81" @default.
• W4283156175 hasPublicationYear "2022" @default.
• W4283156175 type Work @default.
• W4283156175 citedByCount "0" @default.
• W4283156175 crossrefType "proceedings-article" @default.
• W4283156175 hasAuthorship W4283156175A5003941121 @default.
• W4283156175 hasAuthorship W4283156175A5013179086 @default.
• W4283156175 hasAuthorship W4283156175A5022868259 @default.
• W4283156175 hasAuthorship W4283156175A5036405798 @default.
• W4283156175 hasAuthorship W4283156175A5039933427 @default.
• W4283156175 hasAuthorship W4283156175A5054688598 @default.
• W4283156175 hasAuthorship W4283156175A5062869252 @default.
• W4283156175 hasAuthorship W4283156175A5065018139 @default.
• W4283156175 hasAuthorship W4283156175A5089728798 @default.
• W4283156175 hasConcept C126322002 @default.
• W4283156175 hasConcept C167135981 @default.
• W4283156175 hasConcept C197934379 @default.
• W4283156175 hasConcept C203014093 @default.
• W4283156175 hasConcept C2778375690 @default.
• W4283156175 hasConcept C2779134260 @default.
• W4283156175 hasConcept C2779280984 @default.
• W4283156175 hasConcept C535046627 @default.
• W4283156175 hasConcept C71924100 @default.
• W4283156175 hasConcept C72563966 @default.
• W4283156175 hasConcept C90924648 @default.
• W4283156175 hasConceptScore W4283156175C126322002 @default.
• W4283156175 hasConceptScore W4283156175C167135981 @default.
• W4283156175 hasConceptScore W4283156175C197934379 @default.
• W4283156175 hasConceptScore W4283156175C203014093 @default.
• W4283156175 hasConceptScore W4283156175C2778375690 @default.
• W4283156175 hasConceptScore W4283156175C2779134260 @default.
• W4283156175 hasConceptScore W4283156175C2779280984 @default.
• W4283156175 hasConceptScore W4283156175C535046627 @default.
• W4283156175 hasConceptScore W4283156175C71924100 @default.
• W4283156175 hasConceptScore W4283156175C72563966 @default.
• W4283156175 hasConceptScore W4283156175C90924648 @default.
• W4283156175 hasLocation W42831561751 @default.
• W4283156175 hasOpenAccess W4283156175 @default.
• W4283156175 hasPrimaryLocation W42831561751 @default.
• W4283156175 hasRelatedWork W1779912604 @default.
• W4283156175 hasRelatedWork W1972654344 @default.
• W4283156175 hasRelatedWork W2070414885 @default.
• W4283156175 hasRelatedWork W2078916521 @default.
• W4283156175 hasRelatedWork W2115865518 @default.
• W4283156175 hasRelatedWork W2158288456 @default.
• W4283156175 hasRelatedWork W2750760542 @default.
• W4283156175 hasRelatedWork W2792567593 @default.
• W4283156175 hasRelatedWork W4214584206 @default.
• W4283156175 hasRelatedWork W56249736 @default.
• W4283156175 isParatext "false" @default.
• W4283156175 isRetracted "false" @default.
• W4283156175 workType "article" @default.